CTOs on the Move

St. Luke's Episcopal Health System

www.sleh.com

 
Saint Luke's Hospital of Kansas City is a 582-bed tertiary care hospital offering many specialized programs and services, with a network of 550 physicians practicing in more than 56 medical specialties.
  • Number of Employees: 0-25
  • Annual Revenue: > $1 Billion
  • www.sleh.com
  • 6624 Fannin St Ste 1100
    Houston, TX USA 77030-2323
  • Phone: 832.355.1000

Executives

Name Title Contact Details

Similar Companies

Alta Bates Medical Group

Alta Bates Medical Group is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OMBS

OMBS is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southeastern Urological Center PA

Southeastern Urological Center PA is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Tallahassee, FL. To find more information about Southeastern Urological Center PA, please visit www.seuc.com

Wellpoint Health Services

Wellpoint Health Services is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.